Holen Sie sich die Stockscreener-App
4.25
0.00%
-0.000100
Handel nachbörslich:
4.25
Schlusskurs vom Vortag:
$4.2501
Offen:
$4.1872
24-Stunden-Volumen:
732
Relative Volume:
0.15
Marktkapitalisierung:
$212.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-5.7894
EPS:
-0.7341
Netto-Cashflow:
-
1W Leistung:
+5.46%
1M Leistung:
+0.05%
6M Leistung:
+25.37%
1J Leistung:
-29.87%
1-Tages-Spanne:
$4.1872
$4.27
1-Wochen-Bereich:
$3.855
$4.49
52-Wochen-Spanne:
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Vergleichen Sie GNFT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.25 | 212.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-12-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Hochstufung | Stifel | Hold → Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Underperform |
| 2020-05-13 | Herabstufung | Kepler | Buy → Reduce |
| 2020-05-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Bestätigt | B. Riley FBR | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-04-24 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Genfit Adr Aktie (GNFT) Neueste Nachrichten
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs See Mixed Results With Modest Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Finanzdaten der Genfit Adr-Aktie (GNFT)
Es liegen keine Finanzdaten für Genfit Adr (GNFT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):